Composition comprising self-assembled structure, and freeze-dried product thereof

The composition of tocopherol phosphate ester with a divalent or higher valent metal salt and controlled water content stabilizes the self-assembled structure, allowing its use despite polar organic compounds, and is effectively preserved in a lyophilized form.

WO2024253199A1PCT designated stage expired Publication Date: 2024-12-12RESONAC CORP
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2024/020938
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-06-08
Filing Date
2024-06-07
Publication Date
2024-12-12

AI Technical Summary

Technical Problem

Tocopherol phosphate self-assembled structures are unstable in the presence of polar organic compounds, limiting their practical industrial use.

Method used

A composition comprising a self-assembled structure of tocopherol phosphate ester, a divalent or higher valent metal salt, and water, with a molar ratio of the metal salt to tocopherol phosphate between 0.05 and 12, and a water content of 1.0% by mass or less, which can be lyophilized to maintain stability.

Benefits of technology

The composition stably maintains the self-assembled structure even in the presence of polar organic compounds, enabling its practical use and providing a stable dried product.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure JPOXMLDOC01-APPB-C000001
    Figure JPOXMLDOC01-APPB-C000001
  • Figure JPOXMLDOC01-APPB-T000002
    Figure JPOXMLDOC01-APPB-T000002
  • Figure JPOXMLDOC01-APPB-T000003
    Figure JPOXMLDOC01-APPB-T000003
Patent Text Reader

Abstract

Provided is a composition comprising a self-assembled structure of a tocopheryl phosphoric acid ester, a metal salt having a valency of 2 or higher, and water. Also provided is a freeze-dried product comprising a self-assembled structure of a tocopherol phosphoric acid ester and a metal salt having a valency of 2 or higher, wherein the molar ratio of the metal salt having a valency of 2 or higher to the tocopherol phosphoric acid ester is 0.05-12.
Need to check novelty before this filing date? Find Prior Art

Description

Composition containing self-assembled structure and freeze-dried product thereof

[0001] The present invention relates to a composition containing a self-assembled structure and a freeze-dried product thereof. This application claims priority to Japanese Patent Application No. 2023-095106, filed on June 8, 2023, the contents of which are incorporated herein by reference.

[0002] Tocopherol phosphate is an amphiphilic compound in which a phosphate group is introduced into oil-soluble vitamin E. It has been reported that a mixture of tocopheryl phosphate sodium (hereinafter also referred to as "TPNa"), a sodium salt of tocopherol phosphate, and phospholipids forms a nanostructure called "Tocosome," which has been studied as a nutritional supplement, a drug delivery carrier, and the like (Non-Patent Document 1). Recent research has revealed that TPNa, even when used alone, self-assembles in water to form a novel mitochondria-like structure (Non-Patent Document 2), and this structure is expected to be used in industry.

[0003] MR Mozafari, et al., Tocosome: Novel drug delivery system containing phospholipids and tocopheryl phosphates. International Journal of Pharmaceutics. Volume 528, Issues 1-2, 7 August 2017, Pages 381-382. Yuji Yamashita et al., "Unique self-organization behavior of aqueous solutions of vitamin E derivatives," Abstracts of the 73rd Colloid and Interface Chemistry Symposium.

[0004] Tocopherol phosphate esters form self-assembled structures in water, but the self-assembled structures collapse in the presence of polar organic compounds such as alcohols. For practical application of self-assembled structures of tocopherol phosphate esters, it is desirable that the self-assembled structures be stably maintained even in the presence of polar organic compounds. Therefore, an object of the present invention is to provide a composition containing a self-assembled structure of tocopherol phosphate ester, which stably maintains the self-assembled structure, and a dried product of the composition.

[0005] The present invention includes the following aspects. [1] A composition comprising a self-assembled structure of tocopheryl phosphate, a divalent or higher metal salt, and water. [2] The composition according to [1], wherein the divalent or higher metal salt is at least one selected from the group consisting of calcium salts, magnesium salts, and zinc salts. [3] The composition according to [1] or [2], wherein the concentration of the tocopheryl phosphate is 0.001 mM to 100 mM, and the molar ratio of the divalent or higher metal salt to the tocopheryl phosphate is 0.05 to 12. [4] A composition comprising a self-assembled structure of tocopheryl phosphate and a divalent or higher metal salt, wherein the molar ratio of the divalent or higher metal salt to the tocopheryl phosphate is 0.05 to 12, and wherein the water content is 1.0 mass% or less. [5] A lyophilized product of the composition according to any one of [1] to [3].

[0006] According to the present invention, there are provided a composition containing a self-assembled structure of tocopherol phosphate, in which the self-assembled structure is stably maintained, and a dried product of the composition.

[0007] 1 is a photograph of the self-assembled construction of Example 2 observed with a transmission electron microscope (cryo-TEM) at a magnification of 20,000 times. The scale bar is 200 nm.

[0008] Hereinafter, embodiments of the present invention will be described in detail. However, the present invention is not limited to the embodiments shown below. When "to" is used to describe a range of values ​​in this specification, the values ​​at both ends are the upper and lower limits, respectively, and are included in the range.

[0009] (Composition) In one embodiment, the present disclosure provides a composition. The composition of this embodiment contains a self-assembled structure of tocopheryl phosphate, a divalent or higher valent metal salt, and water.

[0010] <Self-assembled structure of tocopherol phosphate> Tocopherol phosphate is a compound in which a phosphate group is introduced into a hydroxy group of tocopherol. Examples of the tocopherol phosphate include compounds represented by the following general formula (1).

[0011] [In the formula, R 1 , R 2 and R 3 each independently represents a hydrogen atom or a methyl group.

[0012] Tocopherol phosphate esters include the R 1 , R 2 , R 3 Depending on the type of α-tocopherol phosphate ester (R 1 , R 2 , R 3 =CH 3 ), β-tocopherol phosphate (R 1 , R 3 =CH 3 , R 2 =H), γ-tocopherol phosphate ester (R 1 , R 2 =CH 3 , R 3 =H), δ-tocopherol phosphate ester (R 1 =CH 3 , R 2 , R 3 = H), ζ 2 -Tocopherol phosphate ester (R 2 , R 3 =CH 3 , R 1 =H), η-tocopherol phosphate (R 2 =CH 3 , R 1 , R 3 =H), etc. The tocopherol phosphate may be any of these tocopherol phosphates. Among these, α-tocopherol phosphate or γ-tocopherol phosphate is preferred, and α-tocopherol phosphate is more preferred.

[0013] The compound represented by the general formula (1) has an asymmetric carbon atom at the 2-position of the chroman ring, and therefore exists as d- and l-stereoisomers as well as a dl-stereoisomer. The tocopherol phosphate ester may be any of these stereoisomers, but the dl-stereoisomer is preferred.

[0014] Among the above, dl-α-tocopherol phosphate and dl-γ-tocopherol phosphate are preferred as tocopherol phosphate, and dl-α-tocopherol phosphate is more preferred.

[0015] The tocopherol phosphate ester that forms the self-assembled structure is preferably dissolved in water or an aqueous solution as an alkali metal salt. Examples of the alkali metal salt of tocopherol phosphate ester include sodium salt of tocopherol phosphate ester and potassium salt of tocopherol phosphate ester, with sodium salt being more preferred. The sodium salt of tocopherol phosphate ester has the advantage of being highly soluble in water and being in the form of powder, making it easy to handle. The alkali metal salt of tocopherol phosphate ester may be used alone or in combination of two or more.

[0016] The alkali metal salt of tocopheryl phosphate may be commercially available or may be produced by a known method. Sodium dl-α-tocopheryl phosphate is commercially available from Resonac Corporation under the product name TPNa (registered trademark) (display name: sodium tocopheryl phosphate).

[0017] Known methods for producing alkali metal tocopherol phosphate include those described in JP-A-59-44375 and WO97 / 14705. Specifically, tocopherol phosphate can be obtained by reacting a phosphorylating agent such as phosphorus oxychloride with tocopherol dissolved in a solvent and then appropriately purifying the resulting solution after the reaction. Furthermore, the alkali metal tocopherol phosphate can be obtained by neutralizing the resulting tocopherol phosphate with an alkali metal hydroxide such as sodium hydroxide.

[0018] A "self-assembled structure of tocopherol phosphate" refers to a structure having a bag-like bilayer membrane formed by molecular association of multiple tocopherol phosphates in water. Such a self-assembled structure is also commonly called a vesicle. In a "self-assembled structure of tocopherol phosphate," the tocopherol phosphate is mostly present as a tocopherol phosphate ion. When an alkali metal salt of tocopherol phosphate is dissolved in water, it usually dissociates into a tocopherol phosphate ion and an alkali metal ion, but a very small amount may become a non-ionized tocopherol phosphate. The self-assembled structure is formed by such a tocopherol phosphate ion and a non-ionized tocopherol phosphate. In this specification, non-ionized tocopherol phosphate and tocopherol phosphate ion may be collectively referred to as "tocopherol phosphate."

[0019] When the pH of the composition is 4 or higher, the proportion of tocopherol phosphate ester present in the composition that becomes non-ionized tocopherol phosphate ester decreases, resulting in the formation of a self-assembled structure. Therefore, the pH of the composition of this embodiment is preferably 4 or higher. The pH of the composition is more preferably 5 or higher, and even more preferably 6 or higher. When the pH is 12 or lower, the rate of hydrolysis of the phosphate ester moiety in the tocopherol phosphate ester structure slows, improving the stability of the composition over time. Therefore, the pH of the composition of this embodiment is preferably 12 or lower. The pH of the composition is more preferably 11 or lower, and even more preferably 10 or lower. The upper and lower limits can be combined in any manner. The pH of the composition is preferably 4 to 12, more preferably 5 to 11, and even more preferably 6 to 10.

[0020] The concentration of the tocopherol phosphate in the composition of this embodiment is preferably 0.001 mM or more, more preferably 0.01 mM or more, and even more preferably 0.1 mM. The concentration of the tocopherol phosphate is preferably 100 mM or less, more preferably 40 mM or less, and even more preferably 10 mM or less. The upper and lower limits can be combined arbitrarily. The concentration of the tocopherol phosphate in the composition of this embodiment is preferably 0.001 to 100 mM, more preferably 0.01 to 40 mM, and even more preferably 0.1 to 10 mM. When the concentration of the tocopherol phosphate in the composition is 0.001 mM or more, a self-assembled structure of the tocopherol phosphate is easily formed. When the concentration of the tocopherol phosphate in the composition is 100 mM or less, transition to a liquid crystal phase is less likely to occur. When the concentration of tocopherol phosphate in the composition of this embodiment is within the range of 0.001 to 100 mM, a self-assembled structure of tocopherol phosphate is easily formed. "mM" means mmol / L.

[0021] <Divalent or higher metal salt> As the divalent or higher metal salt, divalent or trivalent metal salt is preferred, and divalent metal salt is more preferred.As the divalent or higher metal salt, for example, calcium salt, magnesium salt, zinc salt, aluminum salt, iron salt, copper salt, etc. can be mentioned.Among these, due to the reason that it has high biocompatibility, the divalent or higher metal salt is preferably at least one selected from the group consisting of calcium salt, magnesium salt, and zinc salt.More specifically, the divalent or higher metal salt is preferably at least one selected from the group consisting of calcium chloride, magnesium chloride, and zinc chloride.

[0022] The content of the divalent or higher metal salt in the composition of this embodiment is preferably 0.05 or more in terms of a molar ratio relative to 1 mole of tocopherol phosphate. The molar ratio of the divalent metal salt to 1 mole of tocopherol phosphate is preferably 12 or less, more preferably 1 or less, and even more preferably 0.2 or less. The upper and lower limits can be arbitrarily combined. The molar ratio of the divalent metal salt to 1 mole of tocopherol phosphate is preferably 0.05 to 12, more preferably 0.05 to 1, and even more preferably 0.05 to 0.2. When the molar ratio of the divalent or higher metal salt to tocopherol phosphate is 0.05 or more, the stabilization effect of the divalent or higher metal salt on the self-assembled construction is enhanced. When the molar ratio of the divalent or higher metal salt to tocopherol phosphate is 12 or less, the amount of the divalent or higher metal salt is less likely to be excessive. When the molar ratio of the divalent or higher metal salt to the tocopherol phosphate is greater than 1, the tocopherol phosphate may precipitate due to a salting-out effect depending on the concentration of the tocopherol phosphate and / or the type of the metal salt. Therefore, when the molar ratio of the divalent or higher metal salt to the tocopherol phosphate is greater than 1 (preferably 12 or less), it is preferable to appropriately select the concentration of the tocopherol phosphate and the type of the divalent or higher metal salt.

[0023] <Water> Depending on the application, for example, pure water, ultrapure water, ion-exchanged water, purified water, sterilized purified water, water for injection, etc. It is preferable to use cosmetic-grade or pharmaceutical-grade water.

[0024] The content of water in the composition of this embodiment can be the balance of the total amount of the alkali metal salt of tocopheryl phosphate, the divalent or higher metal salt, and any optional components. The content of water in the composition of this embodiment is usually 70% by mass or more and less than 100% by mass, preferably 75% by mass or more and less than 100% by mass, more preferably 80% by mass or more and less than 100% by mass, and even more preferably 85% by mass or more and less than 100% by mass, based on the total mass of the composition.

[0025] If the composition contains a large amount of a compound other than tocopherol phosphate that forms a self-assembled structure by itself, the composition will not be what is intended by the present invention, which is to provide a composition in which a self-assembled structure that also has the properties of a tocopherol phosphate compound is stably maintained. Therefore, the content of the compound other than tocopherol phosphate that forms a self-assembled structure by itself in the composition of this embodiment is preferably 50% by mass or less, more preferably 30% by mass or less, and even more preferably 10% by mass or less, relative to the total mass (100% by mass) of the compounds that form the self-assembled structure. The content of the compound other than tocopherol phosphate that forms a self-assembled structure by itself in the composition of this embodiment is preferably 0% by mass, or may be 0 to 50% by mass, 0 to 30% by mass, or 0 to 10% by mass, relative to the total mass (100% by mass) of the compounds that form the self-assembled structure.

[0026] <Optional Components> The composition of the present embodiment may contain optional components. The optional components are not particularly limited as long as the self-assembled construction is maintained. Examples of optional components include polar organic compounds, and drugs or additives commonly used in pharmaceuticals or cosmetics.

[0027] Examples of polar organic compounds include alcohols, such as monohydric alcohols such as methanol, ethanol, 1-propanol, isopropanol, and 1-butanol, and dihydric alcohols such as 1,3-butylene glycol and ethylene glycol.

[0028] Examples of drugs or additives include nutrients, preservatives, antibacterial agents, whitening agents, vitamins and derivatives thereof, anti-inflammatory agents, anti-inflammatory agents, blood circulation promoters, hormones, anti-wrinkle agents, anti-aging agents, firming agents, cooling agents, warming agents, wound healing promoters, irritation relievers, analgesics, cell activators, plant / animal / microbial extracts, antipruritics, keratin exfoliating / dissolving agents, astringents, enzymes, nucleic acids, fragrances, pigments, colorants, anti-inflammatory analgesics, antifungals, antihistamines, antibiotics, antibacterial substances, herbal medicines, antipruritics, keratin softening / exfoliating agents, antiseptics and disinfectants, antioxidants, pH adjusters, and other additives.

[0029] The self-assembled structure of tocopherol phosphate ester can be observed with a transmission electron microscope or the like to confirm the formation of the self-assembled structure. Therefore, whether the tocopherol phosphate ester forms a self-assembled structure under the conditions in which the optional components are contained in the composition can be confirmed by observing the composition with a transmission electron microscope or the like. The average particle size of the self-assembled structure can be measured by any measurement method. For example, dynamic light scattering measurement can be easily used to measure the average particle size of the self-assembled structure. Using dynamic light scattering measurement, the average particle size of the self-assembled structure can be measured before and after changing the storage conditions of the composition, thereby determining the change in the average particle size due to the storage conditions, etc. By observing the change in the average particle size at this time, if the change is not significant, it can be determined that the self-assembled structure is stable under the storage conditions. For example, to determine the effect of adding an optional component, it is sufficient to observe the change in the average particle size of the self-assembled structure before and after adding the optional component. Typically, if the self-assembled structure is unstable, the average particle size will decrease significantly upon addition of a polar organic compound, etc., and this can indicate that the self-assembled structure has dissociated. Therefore, the optional component can be selected such that the change in the average particle size of the self-assembled construct of tocopherol phosphate is small before and after the optional component is added to the composition.The optional component is preferably a component that the change in the average particle size of the self-assembled construct of tocopherol phosphate is small when the optional component and the polar organic compound are added to the composition.

[0030] <Method for Producing the Composition> The composition of this embodiment can be produced by dissolving an alkali metal salt of a tocopherol phosphate and a divalent or higher metal salt in water. When the composition of this embodiment contains optional components, the optional components may also be dissolved in water. The alkali metal salt of a tocopherol phosphate and the divalent or higher metal salt may be dissolved in water simultaneously or sequentially. Alternatively, an aqueous solution of an alkali metal salt of a tocopherol phosphate and an aqueous solution of a divalent or higher metal salt may be prepared separately and then mixed. Among these methods, a method of preparing individual aqueous solutions of the alkali metal salt of a tocopherol phosphate and the divalent or higher metal salt and then mixing the two is preferred, as this allows for uniform dissolution of the alkali metal salt of a tocopherol phosphate and the divalent or higher metal salt. When the alkali metal salt of a tocopherol phosphate is added to an aqueous solution containing a divalent or higher metal salt and then dissolved, the alkali metal salt of a tocopherol phosphate may remain undissolved. In the method of adding and dissolving a divalent or higher metal salt in an aqueous solution of an alkali metal salt of tocopheryl phosphate, the divalent or higher metal salt may not dissolve uniformly, resulting in cloudiness and precipitation.

[0031] Since the Krafft point (Kp) of an aqueous solution of TPNa is 16.2° C., when TPNa is used as the alkali metal salt of tocopheryl phosphate, the composition of this embodiment is preferably produced at a temperature of 17° C. or higher, more preferably at a temperature of 20 to 80° C. Even when the alkali metal salt of tocopheryl phosphate is other than the sodium salt, the composition of this embodiment is preferably produced at a temperature equal to or higher than the Krafft point of the respective alkali metal salt.

[0032] Any compound (target compound) can also be encapsulated in the self-assembled structure of tocopherol phosphate. For example, an alkali metal salt of tocopherol phosphate can be added to and dissolved in an aqueous solution containing the target compound, followed by mixing with an aqueous solution of a divalent or higher metal salt to produce a self-assembled structure of tocopherol phosphate in which the target compound is encapsulated in the structure. After production of the self-assembled structure, the self-assembled structure may be purified by filtration, column chromatography, ultracentrifugation, or the like. By using a target compound as a nutritional component (e.g., vitamins, amino acids, peptides, sugars, etc.), a drug (anticancer agent, enzyme, inhibitor, hormone, cytokine, etc.), or the like, the self-assembled structure of tocopherol phosphate can be used as a nutritional supplement or a drug delivery carrier. Any component, such as the additives described above, can be appropriately encapsulated in the self-assembled structure.

[0033] The composition of the present embodiment is usually in the form of a self-assembled structure of tocopherol phosphate dispersed in an aqueous solution containing a salt of a divalent or higher metal. The composition of the present embodiment can be said to be an aqueous solution in which a self-assembled structure of tocopherol phosphate is dispersed, or a dispersion of a self-assembled structure of tocopherol phosphate.

[0034] The composition of the present embodiment contains a divalent or higher metal salt, thereby enabling the self-assembled structure of tocopherol phosphate to be stably maintained. Conventional self-assembled structures of tocopherol phosphate cannot maintain their self-assembled structure in the presence of polar organic compounds such as alcohol (e.g., ethanol, 1,3-butylene glycol, etc.). However, when a divalent or higher metal salt is coexisted with a self-assembled structure of tocopherol phosphate, the self-assembled structure of tocopherol phosphate can be stably maintained. While the reason for this is unclear, it is thought that the divalent or higher metal ions function to coat the periphery of the self-assembled structure due to an interaction between phosphate groups located on the exterior of the self-assembled structure of tocopherol phosphate and divalent or higher metal ions. A self-assembled structure of tocopherol phosphate that maintains its shape even in the presence of alcohol or the like is not only convenient for producing a self-assembled structure that retains useful chemical substances therein, but is also useful because it can be used in a wider range of situations.

[0035] (Freeze-dried Product of Self-Assembled Structure) In one embodiment, the present disclosure provides a freeze-dried product of a self-assembled structure. The freeze-dried product of this embodiment includes a self-assembled structure of tocopherol phosphate and a divalent or higher metal salt. The molar ratio of the divalent or higher metal salt to the tocopherol phosphate is 0.05 to 12. The freeze-dried product of this embodiment may also be a freeze-dried product of the composition of the above embodiment, obtained by freeze-drying the composition of the above embodiment. Freeze-drying is a method of freezing an object and then drying it by sublimating water in a vacuum. The freeze-drying of the composition of the above embodiment can be carried out using a known method and a freeze-drying apparatus. The water content of the freeze-dried product is preferably 1.0% by mass or less, more preferably 0.6% by mass or less. The water content of the freeze-dried product can be measured by the Karl Fischer method or the like. The lower limit of the water content of the freeze-dried product may be, for example, 0.001% by mass or more, or 0.01% by mass or more. The range of the water content of the freeze-dried product is, for example, 0.001 to 1.0% by mass, preferably 0.001 to 0.6% by mass.

[0036] The composition of the above embodiment can be freeze-dried to obtain a powder containing a self-assembled structure of tocopherol phosphate. The freeze-dried product retains the self-assembled structure of tocopherol phosphate, and can therefore be used for the same purposes as the above composition. Furthermore, the powder form offers the advantage of ease of handling.

[0037] The present invention will be explained in more detail below with reference to examples and comparative examples, but the present invention is not limited to the following examples.

[0038] Example 1 0.32 g of TPNa (manufactured by Resonac Corporation) was placed in a 100 mL measuring flask and dissolved in ultrapure water (MilliQ) (6 mM TPNa aqueous solution). 2 ・6H 2 0.061 g of Junsei Chemical Co., Ltd. was dissolved in ultrapure water (3 mM MgCl 2In a vial, add 12.5 g of the 6 mM TPNa solution prepared above and 3 mM MgCl 2 2.5 g of the aqueous solution and 10 g of ultrapure water were mixed together to form a solution containing 3 mM TPNa and 0.3 mM MgCl 2 A mixture containing

[0039] 0.95 mL of the mixture was measured out, and 0.05 mL of ethanol (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.) was added (ethanol was approximately 5% by mass), and the mixture was mixed uniformly at room temperature. After standing for one day, dynamic light scattering (DLS) measurement (Zetasizer, manufactured by Spectris Inc.) was performed on the mixture to confirm the formation of a self-assembled structure of TPNa. The mixture was measured while being diluted, and the particle size distribution was analyzed from the autocorrelation function, and the number average particle diameter was calculated.

[0040] Example 2: MgCl 2 ・6H 2 CaCl instead of O 2 ・2H 2 The experiment was carried out in the same manner as in Example 1, except that 0.044 g of PEG-100 (manufactured by Junsei Chemical Co., Ltd.) was used.

[0041] (Comparative Example 1) 3 mM MgCl 2 ・6H 2 The experiment was carried out in the same manner as in Example 1, except that ultrapure water was used instead of the O aqueous solution.

[0042] Example 3 An experiment was carried out in the same manner as in Example 1, except that 1,3-butylene glycol (1,3-BG, High Sugar Cane BG, manufactured by Kokyu Alcohol Kogyo Co., Ltd.) was used instead of ethanol.

[0043] Example 4 An experiment was carried out in the same manner as in Example 2, except that 1,3-BG was used instead of ethanol.

[0044] Comparative Example 2 An experiment was carried out in the same manner as in Comparative Example 1, except that 1,3-BG was used instead of ethanol.

[0045] (Example 5) 1.25 g of 6 mM TPNa aqueous solution and 3 mM MgCl 20.25 g of the aqueous solution was added to 27 g of ultrapure water, and 0.3 mM TPNa and 0.03 mM MgCl 2 The experiment was carried out in the same manner as in Example 1, except that a mixed solution containing

[0046] Example 6 MgCl 2 ・6H 2 CaCl instead of O 2 ・2H 2 The experiment was carried out in the same manner as in Example 5, except that 0.044 g of PEG-100 (manufactured by Junsei Chemical Co., Ltd.) was used.

[0047] The mixed solutions prepared in Examples 1 to 6 and Comparative Examples 1 and 2 were observed under a transmission electron microscope to confirm the formation of a self-assembled structure, and the results were evaluated according to the following evaluation criteria, and are shown in "Self-assembled structure" in Table 1. Figure 1 shows a transmission electron microscope (cryo-TEM) image (magnification 20,000 times) of the mixed solution prepared in Example 2. <Evaluation criteria> A: A self-assembled structure was observed. B: A self-assembled structure was not observed.

[0048] For the mixed solutions prepared in Examples 1 to 6 and Comparative Examples 1 and 2, the number average particle diameter was calculated based on the results of dynamic light scattering measurement, and the results are shown in "Average particle diameter (nm)" in Table 1.

[0049]

[0050] The results of dynamic light scattering measurements showed that in Comparative Examples 1 and 2, the particle size decreased with the addition of ethanol or 1,3-BG (i.e., the self-assembled structure dissociated). In contrast, in Examples 1 to 4, no change in particle size was observed, indicating that the self-assembled structure was stably maintained. Examples 5 and 6 confirmed the formation of a self-assembled structure even when the concentrations of TPNa and divalent or higher metal salts were lower.

[0051] (Example 7) As in Example 1, a 6 mM TPNa aqueous solution and a 3 mM MgCl 2 An aqueous solution was prepared. A 6 mM TPNa solution and 3 mM MgCl were placed in a vial. 2 The final concentration of TPNa was 3 mM, MgCl 2The mixture was mixed so that the final concentrations were 0.15 mM, 0.2 mM, 0.3 mM, 0.4 mM, 0.6 mM, 1.2 mM, 3 mM, 6 mM, or 12 mM. The appearance of the mixed solution was visually observed and judged based on the following evaluation criteria, and the results are shown in "Judgment" in Table 2. <Evaluation criteria> A: A transparent appearance was maintained. B: Cloudiness occurred. C: Precipitation was observed.

[0052]

[0053] (Example 8) Final concentration of TPNa was 0.1 mM, MgCl 2 The experiment was carried out in the same manner as in Example 7, except that the final concentration of was 0.15 mM, 0.2 mM, 0.3 mM, 0.4 mM, 0.6 mM or 1.2 mM. The results are summarized in Table 3.

[0054] From the results of Examples 7 and 8, it was confirmed that the molar ratio of the divalent or higher metal salt to TPNa is preferably in the range of 0.05 to 12. It was also confirmed that when the concentration of TPNa is high, the molar ratio of the divalent or higher metal salt to TPNa is preferably 1 or less.

[0055] Example 9: As in Example 1, first, 3 mM TPNa and 0.3 mM MgCl 2 A mixed solution containing the above was obtained. The average particle size of the self-assembled structure at this point was 58.07 nm. This mixed solution was frozen overnight at -35°C in a freezer and then subjected to a freeze dryer (EYELA FDU 2100) for two days to obtain a white powder. The moisture content of the powder was measured by the Karl Fischer method using an automatic moisture analyzer (HIRANUMA, AQV-300) and found to be 0.6% by mass. The entire amount of this powder was redissolved in the same amount of water as before drying, and the average particle size was measured. It was confirmed that the redissolved composition contained a self-assembled structure with an average particle size of 89.78 nm. Ethanol was added to the obtained composition in the same manner as in Example 1, and the average particle size of the self-assembled structure was measured in the same manner as above, resulting in an average particle size of 85.32 nm. These results confirmed that the self-assembled structure of TPNa was stably maintained in the redissolved composition.

[0056] Example 10: MgCl 2 ・6H 2 CaCl instead of O 2 ・2H 2 An experiment was performed using the same procedure as in Example 9, except that 0.044 g of TPNa was used. The average particle size of the self-assembled structure before freeze-drying was 123.63 nm. Freeze-drying yielded a white powder with a water content of 0.5% by mass. Redissolution yielded a composition containing a self-assembled structure with an average particle size of 149.70 nm. When ethanol was added to the obtained composition in the same manner as in Example 2, the average particle size was 140.75 nm. These results confirmed that the self-assembled structure of TPNa was stably maintained in the redissolved composition.

[0057] Although the preferred embodiments of the present invention have been described above, the present invention is not limited to these embodiments. Addition, omission, substitution, and other modifications of the configuration are possible within the scope of the spirit of the present invention. The present invention is not limited by the above description, but is limited only by the scope of the appended claims.

Claims

1. A composition comprising a self-assembled structure of a tocopherol phosphate ester, a salt of a divalent or higher metal, and water.

2. The composition according to claim 1, wherein the divalent or higher metal salt is at least one selected from the group consisting of calcium salts, magnesium salts, and zinc salts.

3. The composition according to claim 1 or 2, wherein the concentration of the tocopherol phosphate is 0.001 mM to 100 mM, and the molar ratio of the divalent or higher metal salt to the tocopherol phosphate is 0.05 to 12.

4. A composition comprising a self-assembled structure of tocopherol phosphate and a divalent or higher metal salt, wherein the molar ratio of the divalent or higher metal salt to the tocopherol phosphate is 0.05 to 12, and the water content is 1.0 mass% or less.

5. A lyophilized product of the composition according to claim 1 or 2.

Citation Information

Patent Citations

  • Stable aqueous solution of alpha-tocopherol phosphoric ester

    JP1984044375A

  • Game machine

    JP2023095106A

  • Detergent composition

    CN108251228A

  • cosmetic

    JP1992208209A

  • High-purity tocopherol phosphates, process for the preparation thereof, method for analysis thereof, and cosmetics

    WO1997014705A1